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Received March 19, 2013; accepted July 19, 2013AbstractBackground: Glycogen-synthase kinase 3 (GSK3) is involved in many signaling pathways and is associated with a host of high-profile path-
ophysiological states. However, its role in morphine tolerance, especially naloxone-precipitated withdrawal syndrome, has not been well
investigated. The present study was undertaken to study the role of GSK3 in chronic morphine exposure.
Methods: Adult male SpragueeDawley rats were subjected to intraperitoneal (i.p.) injections of morphine (10 mg/kg) twice daily for 6
consecutive days, and tail-flick tests were conducted to evaluate changes of morphine-induced antinociception. GSK3 inhibitor, SB216763 or
SB415286, was i.p. injected prior to morphine to investigate the influences on morphine tolerance. There were four groups receiving morphine
plus vehicle (2% dimethyl sulfoxide), morphine plus SB216763 (0.6 mg/kg) or SB415286 (1.0 mg/kg), GSK3 inhibitor alone, or dimethyl
sulfoxide: as the control group. On Day 7, naloxone (i.p., 1 mg/kg) was administered and naloxone-precipitated withdrawal behaviors were
individually compared between groups.
Results: Repeated morphine exposure in this study led to progressive shortening of tail-flick latencies and produced six of nine observed
naloxone-precipitated withdrawal behaviors. Coadministration with SB216763 or SB415286 significantly prevented antinociceptive tolerance
and alleviated parts of withdrawal syndrome. Both inhibitors could similarly reverse withdrawal behaviors including grooming, chewing, and
ptosis, but did not affect withdrawal behaviors of penis licking and defecation.
Conclusion: The results demonstrate the importance of GSK3 in reducing chronic morphine-induced tolerance and withdrawal syndrome.
Although GSK3 is involved in diverse physiological functions, aiming at GSK3-related pathway could still be a potential tool to improve
therapeutic quality in clinical morphine treatment.
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Morphine is widely used in relieving pain in medical care
such as cancer pain, chronic pancreatitis, neuropathic pain,
and somatic pain in aged patients who are contraindicated tohinese Medical Association. All rights reserved.
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often accompanied with the development of analgesic toler-
ance and risk of withdrawal symptoms, which force patients to
escalate the doses to achieve an adequate analgesic effect and
be very cautious of abrupt cessation of morphine use. Also,
chronic morphine users easily become dependent on drugs and
are susceptible to addiction. All the above conditions ulti-
mately diminish the clinical usefulness of morphine and lead
to socioeconomical problems.1e3
A growing list of molecules, such as excitatory amino acid
receptors,4e7 adenyl cyclase/cAMP/PKA pathway,8,9 MAPK/
ERK,10 protein kinase C translocation and activation, and ni-
tric oxide release,11,12 have been recognized as the targets
altered by repeated opiate administrations, and are advocated
to be involved in morphine tolerance. Meanwhile, new evi-
dence has revealed that phosphatidylinositol 3-kinase/Akt
cascade may also participate in regulating opiate-induced re-
sponses via phosphorylating the downstream effector,
glycogen synthase kinase-3 b (GSK3b), particularly after
chronic administration of morphine. Supporting data indicate
that acute application of opioid agonists stimulated m-opioid
receptor and subsequently enhanced Akt activity in vitro13,14
and in vivo15; however, repeated morphine treatments signifi-
cantly depressed the Akt phosphorylation level.15 In addition,
coinjections of GSK3 inhibitors, such as lithium salt,16,17 BIO,
or SB216763,18 with morphine were found to attenuate the
chronic morphine-induced tail-flick tolerance in rodents in
responses to thermal stimulation. Parkitna et al18 further
claimed that reversal efficacy was always associated with an
increase in abundance of GSK3b phosphorylation.
GSK3 is a cellular Ser/Thr kinase originally found to be
involved in glucose synthesis, and was soon recognized as an
important intracellular signaling involved in regulating cell
cycle, development, oncogenesis, and neuroprotection.19
Lithium, a nonselective GSK3 inhibitor has long been used in
bipolar disease, and recently, diverse types of GSK3 inhibitors
have been proposed as potential therapeutic agents for diseases
such as diabetes, Alzheimer’s disease, and colon cancer20 in
preclinical studies. Although the significance of GSK3 in
modulating morphine function has been stated,17,18,21,22 the
only tested effect on tolerance was given via intrathecal route,
but no data regarding withdrawal syndrome are available. We
designed this study using systemic administration of morphine
with different GSK3 inhibitors to investigate the effects on
nociceptive thresholds and naloxone-precipitated withdrawal
behaviors following chronic morphine exposure. The study’s
purposes were to explore the role of GSK3 signaling pathway in
ameliorating chronic morphine-induced complications and
serve as a preclinical study for potential clinical application.
2. Methods2.1. Animal preparationsThe study was performed on male SpragueeDawley rats
(weighing 200e250 g). Rats were housed in groups of three in
an environment of 23  0.5C with a 12-hour dark/light cycle.Food and water were available ad libitum. All experimental
procedures were conducted in accordance with guidelines
approved by the Guidelines for the Care and Use of Experi-
mental Animals of Shin-Kong Memorial Hospital (Taipei,
Taiwan), which was based on the Codes for Experimental Use
of Animals from the Council of Agriculture, Taiwan.2.2. Drug injectionsThere were two types of GSK3 inhibitors, SB216763 and
SB415286 (Tocris Cookson Ltd., Bristol, Avon, UK), used in
this study. They were initially dissolved in dimethyl sulfoxide
(DMSO) and were then diluted to adequate concentrations for
injection with a final DMSO concentration of 2%. Therefore,
2% DMSO solution was used as a vehicle in the control group.
The selected doses of SB216763 and SB415286 had been
reported in previous heart reperfusion studies for providing a
cardioprotective effect.22e25 Animals were randomly divided
into four groups (at least 7 rats in each group) as follows: (1)
morphine plus vehicle group (Mor-Veh): morphine was
intraperitoneally (i.p.) injected at a dose of 10 mg/kg 30 mi-
nutes after vehicle administrations (2% DMSO at a volume of
1 mL/kg, i.p.) twice/day (at 09:00 and 17:00) for 6 successive
days; (2) morphine plus GSK3 inhibitor (Mor-S2 or Mor-S4)
group: SB216763 (i.p., 0.6 mg/kg) or SB415286 (i.p., 1 mg/
kg) prior to morphine injections at the same time course in the
Mor-Veh group; (3) DMSO (Veh) group: animals were sub-
jected to i.p. DMSO as the naı¨ve control; and (4) SB (S2 or
S4) group: rats received SB216763 or SB415286 alone as the
sham control. Drugs in Veh and SB control groups were given
according to the abovementioned protocol for 6 days. All four
groups received an injection of morphine (i.p., 10 mg/kg) on
the morning of Day 7. To investigate morphine abstention-
induced withdrawal syndrome, subcutaneous naloxone
(1 mg/kg) was injected in the Mor-Veh, Mor-S2, and Mor-S4
groups 2 hours after the last morphine injections on the Day 7
of the experiment.2.3. Nociceptive threshold testsTail-flick response to an external heat nociception was used
to evaluate the analgesic effect of morphine. The test latency
was defined as the duration of a withdrawal reaction to a
radiant heat projection from an algesic machine (Tail Flick
Analgesia Meter MK-303B, Muromachi Kikai, Tokyo, Japan).
The heat intensity of the light bulb was set to result in basal
latencies within 6e8 seconds, and the cutoff time was set at 15
seconds. The tail flick responses to different treatments were
examined 30 minutes after drug injections on Day 1, Day 2,
Day 3, Day 5, and Day 7. Baseline withdrawal threshold, i.e.,
“basal latency”, was determined 2 days prior to the experi-
ment. At each time-point, three tail flick tests separated by at
least 2-minute intervals were measured and averaged as the
“test latency”. The percentage of maximal possible anti-
nociceptive effect (MPE) representing the analgesic result is
defined by the equation: MPE% ¼ [(test latency  basal la-
tency)/(cutoff time  basal latency)]  100.
33W.-W. Liao et al. / Journal of the Chinese Medical Association 77 (2014) 31e372.4. Withdrawal behavior observationAnimals in the Mor-Veh and Mor-S2 or Mor-S4 groups
(n ¼ 6 each) were subcutaneously injected with naloxone at a
dose of 1 mg/kg 2 hours after morphine on the morning of Day
7. Data from a separate group of naı¨ve rats receiving saline
alone for 7 days was used as the control group (Veh) for
comparison. Immediately after naloxone injection, the rat was
placed in a transparent Plexiglas box for observation of two
classes of withdrawal behaviors, a method modified from
previous study.26 One class was measured by occurrences,
such as grooming, mouth chewing, teeth chattering, penis
licking, wet-dog shake, and jumping by numbers of bouts,
whereas the other class was evaluated by durations within 30
minutes, including ptosis and rearing (or exploring). Stools,
either dry or watery, during this period were weighed. The
withdrawal score was calculated as the sum of occurrence
numbers or time for all signs.2.5. Statistical analysisFig. 1. Effect of two GSK3 inhibitors, SB216763 and SB415286, on the
development of morphine tolerance. Morphine was intraperitoneally (i.p.)
injected at a dose of 10 mg/kg twice daily for 6 consecutive days and once in
the morning on Day 7. Tail-flick latencies were measured 30 minutes after
morphine administrations. (A) SB216763 (i.p., 0.6 mg/kg) or vehicle (2%
dimethyl sulfoxide: DMSO, 1 ml/kg) were injected 30 min prior to morphine
in the Mor-S2 group or the Mor-Veh group, respectively. Two control groups
(the Veh and S2 group) received i.p. injections of 2% DMSO or SB216763,
respectively (n ¼ 8 or n ¼ 9 for each group). (B) SB415286 (i.p., 1.0 mg/kg)
or vehicle (2% DMSO, 1 ml/kg) were injected following the same protocol.In the morphine tolerance experiment, tail-flick latencies at
different time points among the four groups were compared
via two-way analysis of variance (ANOVA; SigmaStat, Systat
Software, San Jose, CA, USA). In addition, repeated mea-
surement of ANOVA was applied to assess the daily changes
prior to and after the drug administrations in individual
groups, and one-way ANOVA with post hoc Tukey’s test was
applied to compare between-group differences after drug
treatments at each time point. One-way ANOVAwith post hoc
Tukey’s test was used for the comparison of withdrawal be-
haviors among multiple groups. Differences with p < 0.05
were considered statistically significant.
3. Results
(n ¼ 7e9 for each group) All data are presented as means  standard devi-
ation. *** p <0.001; vs. the Veh group; # p <0.05, ### p <0.001; the Mor-S2
(A) or Mor-S4 (B) group vs. the Mor-Veh group.3.1. Effects of GSK3 inhibitor on morphine
antinociception and toleranceAs expected, initial morphine injections elicited strong
antinociception, evidenced by significant increase of with-
drawal latencies in the tail-flick test (Fig. 1). Repeated
administration of morphine in the Mor-Veh group led to
tolerance phenomenon, demonstrated by the gradual decline of
MPE% from a value of nearly 100% on Day 1, Day 2, and Day
3 to 59.06  21.06% ( p ¼ 0.02 vs. Day 3) and
84.33  10.60% ( p ¼ 0.03 vs. Day 3) on Day 5, and then to
22.38  23.90% ( p ¼ 0.034 vs. Day 5) and 26.99  26.38%
( p ¼ 0.001 vs. Day 5) on Day 7 in Fig. 1A and 1B, respec-
tively. Coinjection of SB216763 with morphine (the Mor-S2
group) did not differ in MPE% from those in the Mor-Veh
group on Day 1, Day 2, and Day 3; however, SB216763
preserved antinociceptive responses and showed significant
difference on Day 5 (86.68  18.46% in the Mor-S2 group vs.
Mor-Veh, p ¼ 0.039) and Day 7 (84.53%  14.15% in the
Mor-S2 vs. Mor-Veh, p <0.001; Fig. 1A). SB415286 had a
similar effect on morphine tolerance but showed less evident(Fig. 1B). However, neither DMSO in 2% concentration (the
Veh group) nor SB treatment (the S2 or S4 group) showed
basal changes in MPE% following repeated injections. The tail
flick responses to morphine injection on Day 7 in both control
groups exhibited normal analgesic responses, indicating that
GSK3 inhibitor per se did not alter physiological thermal
threshold.3.2. Effects of GSK3 inhibitor on morphine withdrawal
syndromeBoth GSK3 inhibitors, SB216763 and SB415286, not only
reversed chronic morphine-induced tolerance, but also showed
prevention of morphine withdrawal syndrome in a similar
pattern. Behavioral signs of naloxone-precipitated morphine
withdrawal symptoms appeared immediately after naloxone
injection and persisted during the 30-minute observation in the
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trol (Veh) group (Figs 2 and 3). Due to very low incidence of
wet dog shakes, jumping, and rearing behaviors in all groups,
they were excluded from our plot. Various levels of naloxone-
precipitated withdrawal behaviors appeared after chronic
morphine exposure and those with significant differences
included grooming, chewing, ptosis, chattering, penile licking,
and defecation (stool weight). Comparing between the Mor-
Veh group and the Mor-S2/S4 group, both inhibitors could
similarly reduce behaviors of grooming, chewing, and ptosis,
but had no effect on diarrhea (stool weight). There were milder
variations in drug effect between the two inhibitors. Teeth-
chattering was inhibited only by SB216763 (Fig. 2) and
penile licking only by SB415286 (Fig. 3). Most signs of the
withdrawal syndrome disappeared 2 hours after naloxone
injection.Fig. 2. Consistent coadministration of morphine with SB216763 alleviated naloxon
injected at a dose of 1 mg/kg 2 hours after the last morphine/vehicle administratio
DMSO), and SB216763 (0.6 mg/kg) was injected 30 minutes prior to morphine. V
SB216763. Data are presented as means  standard deviation. One-way ANOVAwi
## p <0.01, ### p <0.001 between the Mor-Veh and the Mor-S2 (n 6 for each4. Discussion
Morphine is an exogenous opioid mainly acting at the
m-opioid receptors as well as affecting a great diversity
of receptors and intracellular signal factors to produce a wide-
range of cellular functions. When given chronically, morphine
leads to disorders such as tolerance and withdrawal phenom-
enon, which are commonly identified in chronic pain pa-
tients.27 In this study, intraperitoneal injection of the GSK3
inhibitor prior to morphine administration significantly atten-
uated the development of analgesic tolerance. Furthermore, we
proved that several withdrawal behaviors including grooming,
chewing, ptosis, and chattering were effectively alleviated by
coadministration of GSK3 inhibitor and morphine. These
findings strongly support the involvement of GSK3 in modi-
fying chronic morphine-induced complications.e-precipitated morphine withdrawal behaviors. Naloxone was subcutaneously
n. Rats were subjected to 7-day morphine or vehicle (2% dimethyl sulfoxide:
eh: 2% DMSO; Mor-Veh: Morphine plus 2% DMSO; Mor-S2: morphine plus
th post hoc Tukey’s test, * p <0.05, *** p <0.001 vs. the Veh group; # p <0.05,
group).
Fig. 3. Consistent coadministration of morphine with SB415286 alleviated naloxone-precipitated morphine behaviors. Naloxone was subcutaneously injected 2
hours after the last morphine/vehicle administration. Veh: 2% dimethyl sulfoxide; Mor-Veh: Morphine plus 2% dimethyl sulfoxide; Mor-S4: morphine plus
SB415286 (1.0 mg/kg). Data are presented as means  standard deviation. One-way ANOVAwith post hoc Tukey’s test, * p <0.05, ** p <0.05, *** p <0.001 vs.
the Veh group; # p <0.05, ## p <0.01 between the Mor-Veh and the Mor-S4 (n 6 for each group).
35W.-W. Liao et al. / Journal of the Chinese Medical Association 77 (2014) 31e374.1. Pharmacological considerationsThe participation of GSK3b in opioid signaling was
initially noted by alterations of analgesic effectiveness and
dependence behavior when animals were coadministrated with
morphine and lithium salt, the latter was recognized as a
GSK3 inhibitor.18,28 However, the precise therapeutic effect of
lithium is ill-defined due to the nonselective effect of lithium
on GSK3b. For example, administration of lithium alone was
found to produce longer response latency in a hot-plate escape
test,29 whereas no antinociceptive effect was observed in
a tail-flick test.16 Dehpour et al16 reported that lithiummodulated morphine-induced analgesia depending on the
lithium quantity, in that doses below 1 mg/kg depressed
morphine antinociception but a higher dose of the drug at a
dose of 10 mg/kg potentiated the effect. More recently, Par-
kitna et al18 reported that with intrathecal injection of two
specific GSK3 inhibitors, BIO (5 ng, 0.5 ng, and 0.05 ng) or
SB216763 (50 ng, 5 ng, 0.5 ng, 0.05 ng), 30 minutes prior to
i.p. morphine administration (10 mg/kg, twice/day) for 8
consecutive days, the tail flick latencies were maintained close
to 90% of baseline level when SB216763 was above a dose of
5 ng. Because interthecal injection is not a feasible technique
for clinical routine practice, we proved in this study that
36 W.-W. Liao et al. / Journal of the Chinese Medical Association 77 (2014) 31e37systemic administration could equally produce the effect.
Comparing the doses between the two studies, i.p. SB215763
at a dose of 0.6 mg/kg is larger than that given via the intra-
thecal route, by about 20,000 times. Undoubtedly, the extreme
high potency in Parkitna and colleagues’ study18 can be
attributed to the intrathecal agent acting directly on the spinal
cells, whereas the i.p. injected agent has to be systemically
absorbed and overcome the bloodebrain barrier. Nevertheless,
interthecal injection of the drug at the lumbar levels may have
a property of localized distribution, which makes it unable to
predict to what extent SB215763 could spread to the supra-
spinal level and whether SB215763 could affect brain reward/
adaptive-related structure, which controls most substance
abstinence-induced withdrawal syndromes.30,31 It is rational to
presume that systemic delivery of SB216763 provides better
central nervous distribution and equilibrium of effect on both
analgesic tolerance and withdrawal syndromes.
The two GSK3 inhibitors used in this study, SB216763 and
SB415286, showed similar effects on morphine tolerance and
withdrawal syndrome, however, their potencies may differ and
can only be confirmed when dose-effect analyses are available.
In addition to numerous cellular studies exploring GSKb ac-
tivities in various biological functions, there were few in vivo
studies with direct animal evidence, and fewer to show the
dose-response relationship. Among them, only two in vivo
studies indicated that systemic SB215763 injection could
penetrate the bloodebrain barrier to produce central nervous
system effect.32,33 With so few preclinical studies, the present
study can be a high-value reference and encourage more
pharmacodynamic experiments in animals.4.2. Possible mechanism underlying Akt/GSK3-mediated
morphine effectsThe present study suggests that chronic morphine exposure
could alter the basal activity of GSK3 distributed in the ner-
vous system, and that the active form of GSK3 may play a
crucial role in the induction of tolerance and withdrawal
symptoms. Growing evidence has yielded to one contention,
that altered Akt/GSK3 signaling may be related to the devel-
opment of tolerance and withdrawal behaviors. In a cell line
transfected with the m-opioid receptor cDNA, Akt has been
validated to be activated in opioid signaling because the
application of opioid agonists, morphine or D-Ala2, N-Me-
Phe4, Gly5-ol enkephalin (DAMGO) enhanced the immuno-
reactive signal of the phosphorylated Akt13,14 within 2 hour.
Further, Muller and Unterwald15 directly examined the influ-
ence of acute and chronic morphine exposure on Akt activity
in rats, and found that in the nucleus accumbens, a region that
dominates the dependence behaviors, phospho-Akt level was
significantly upregulated upon acute morphine exposure, but
phospho-Akt was inhibited by chronic morphine administra-
tions for 6 days or 10 days. In particular, these changes were
effectively abolished by pretreatment with naltrexone, indi-
cating that the Akt activity is inversely regulated depending
on whether there are acute or chronic morphine actions on
opioid receptors. We speculated that prolonged morphineadministration may upregulate GSK3 activity in specific brain
and spinal cord regions via modulating phosphorylated-Akt
levels to enhance morphine tolerance, withdrawal behaviors,
and dependence. Finally, GSK3 is a multi-functional kinase
constitutively acting in diverse physiological processes by
interacting with Wnts, hedgehog, growth factors, and many G-
protein-coupled ligands.34 To improve the specificity of GSK3
on morphine-induced side effects, investigations on molecular
mechanisms are necessary to differentiate the selectivity in
functions of Akt/GSK3b modulating cascade.
In conclusion, based on the present findings, we conclude
that inhibition of GSK3 activity improves the quality of pro-
longed morphine administration. It is therefore implied that
modulating GSK3-mediated activity could be a useful thera-
peutic option to treat chronic morphine-induced complications.Acknowledgments
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